Mark Fitzpatrick

Mark Fitzpatrick joined Flagship Pioneering in 2024, as Partner and Chief Financial Officer of Growth. In this role, he helps to scale and grow Flagship-founded companies and collaborates closely with Flagship and company executive teams to create and deliver value creation strategies.

Mark has over 30 years of leadership experience in the life sciences. Most recently, he was CEO of Versantis AG, a Swiss-based clinical-stage biotechnology company specializing in liver disease acquired by Genfit (NASDAQ:GNFT) in 2022. Previously, Mark served as CEO, President and Principal Financial Officer of Chiasma, Inc. (NASDAQ:CHMA), a commercial stage biotechnology company acquired by Amryt Pharma PLC (NASDAQ:AMYT) in 2021. During his tenure at Chiasma, he led the team developing MYCAPSSA for acromegaly, guiding it from an FDA complete response letter in 2016 to obtaining FDA approval in 2020. Mark also held Chief Financial Officer positions at several public and private biotechnology companies, including Aegerion Pharmaceuticals, Proteon Therapeutics, RenaMed Biologics, Dynogen Pharmaceuticals and Diacrin, Inc. He began his career at Arthur Andersen & Co., before entering the biotech industry at Repligen Corporation, where he worked in accounting and financial management.

Mark has served as a board director for Versantis AG and Chiasma, Inc., and as the audit committee chair of the board of Allena Pharmaceuticals, Inc. He was also a member of the board of directors of Stone Rehabilitation and Senior Living in Newton, MA for 17 years.

Mark received a bachelor’s degree in accounting from Boston College in 1984 and was awarded a CPA certificate in the Commonwealth of Massachusetts in 1987.